HONG KONG – A number of relatively young biopharma companies plan to issue shares on China's stock markets over the next few months, prompted by the lifting late last year of a ban on new issues.
HONG KONG – Despite all the talk of the bright future of China's biotech industry, the sector in this huge country remains in its infancy. Challenges in areas like funding and regulatory procedures have to be taken into account before stepping into the market, said investors at the Asia Biotech Invest conference.
HONG KONG – By 2017, the global pharmaceutical market will be worth $1.2 trillion and $250 billion will come from Asia. Those large sums of money should create multiple opportunities for investors that understand the nuances of the region, said industry insiders gathered here.
HONG KONG – Chinese biopharmaceutical companies are upping the ante in the development of biological drugs and biosimilars of existing best sellers, many of them looking to capitalize on the huge domestic market.
HONG KONG – A framework of the guidelines for biosimilar approvals in China should be released in June, and work proceeds apace to have regulations in place by the end of the year, industry insiders told BioWorld Asia.
HONG KONG – Chinese biopharmaceutical companies are upping the ante in the development of biological drugs and biosimilars of existing bestsellers, many of them looking to capitalize on the huge domestic market.
HONG KONG – A framework of the guidelines for biosimilar approvals in China should be released in June, and work proceeds apace to have regulations in place by the end of the year, industry insiders told BioWorld Today.
